OS7.1 Impact of the addition of Rituximab to standard therapy with high dose methotrexate on health-related quality of life in primary central nervous system lymphoma patients
| Autor: | M. van der Meulen, J.K. Doorduijn, M J B Taphoorn, Katerina Bakunina, M. J. van den Bent, Samar Issa, Jacoline E C Bromberg, L Dirven |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Oncology
Health related quality of life Cancer Research medicine.medical_specialty business.industry Primary central nervous system lymphoma Whole brain irradiation medicine.disease High dose methotrexate Chemotherapy regimen humanities Internal medicine Oral Presentations medicine Methotrexate Rituximab Neurology (clinical) business Standard therapy medicine.drug |
| Zdroj: | Neuro Oncol |
| ISSN: | 1523-5866 1522-8517 |
| DOI: | 10.1093/neuonc/noz126.044 |
| Popis: | BACKGROUND Data on the impact of treatment with Rituximab on health-related quality of life (HRQoL) in primary central nervous system lymphoma (PCNSL) patients are scarce. To determine the net clinical benefit of a new treatment, analyzing the effect on HRQoL is warranted. MATERIAL AND METHODS Patients from a phase III trial (HOVON 105/ ALLG NHL 24), randomized to standard chemotherapy with or without Rituximab, were asked to fill in the EORTC QLQ-C30 and QLQ-BN20 questionnaires before and during treatment, and up to 2 years follow-up or progression. Five predetermined scales were selected for primary analyses: global health status (GH), role (RF) and social functioning (SF), fatigue (FA), and motor dysfunction (MD). A difference ≥10 points was defined as clinically relevant. Cross-sectional analyses were performed comparing changes in HRQoL scores from baseline between the two arms at 12 and 24 months after treatment. Effect of whole brain radiotherapy (WBRT) was analyzed in irradiated patients only. Differences in HRQoL over time between the treatment arms, i.e. the primary outcome, were assessed using linear mixed models (LMM). RESULTS 175/199 patients completed at least one HRQoL questionnaire, and compliance was >60% at all evaluation points. Median age was 61 (IQR 55–66), 74% had a WHO performance score CONCLUSION Treatment resulted in improved HRQoL, but the addition of Rituximab to standard chemotherapy did not further impact HRQoL over time. WBRT did not result in deterioration of HRQoL up to 2 years of follow-up. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|